Target Name: ZNF627
NCBI ID: G199692
Review Report on ZNF627 Target / Biomarker Content of Review Report on ZNF627 Target / Biomarker
ZNF627
Other Name(s): zinc finger protein 627 | FLJ90365 | Zinc finger protein 627 | ZNF627 variant 1 | Zinc finger protein 627 (isoform 1) | Zinc finger protein 627, transcript variant 1 | ZN627_HUMAN

ZNF627: A Potential Drug Target and Biomarker for parkinson's disease

Parkinson's disease is a neurodegenerative disorder characterized by symptoms such as tremors, rigidity, bradykinesia, and postural instability. It affects millions of people worldwide and is often treated with medications that can alleviate symptoms but do not slow down the progression of the disease. ZNF627, a gene that has been identified as a potential drug target for parkinson's disease, has the potential to change this.

The ZNF627 gene is a non-coding RNA molecule that has been shown to play a role in the development and progression of several neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. It is located on chromosome 12q and has been shown to be involved in the regulation of various cellular processes that are important for the survival and growth of neurons.

Studies have suggested that ZNF627 may be a potential drug target for parkinson's disease because it is involved in the synthesis and degradation of a protein called Tau, which is a hallmark protein of Alzheimer's disease and is involved in the formation of neurofibrillary tangles and beta-amyloid plaques. Tau is also involved in the regulation of the trafficking of dopamine-producing neurons, which are lost in Parkinson's disease.

In addition to its role in the regulation of Tau, ZNF627 has also been shown to be involved in the regulation of other proteins that are important for the survival and growth of neurons. It has been shown to play a role in the regulation of the cell cycle, the process by which cells grow and divide, and it has been shown to be involved in the regulation of the autophagy process, the process by which cells break down and recycle their own damaged or unnecessary parts.

The potential drug target status of ZNF627 is supported by several lines of evidence. For example, studies have shown that inhibiting the activity of ZNF627 using small molecules has the potential to protect dopamine-producing neurons from the neurotoxicity of Parkinson's disease. This suggests that targeting ZNF627 may be an effective way to treat Parkinson's disease.

Another line of evidence for the potential drug target status of ZNF627 comes from preclinical studies. For example, studies have shown that overexpression of ZNF627 in mice can cause symptoms similar to Parkinson's disease, including tremors, bradykinesia, and postural instability. This suggests that ZNF627 may be an effective target for the treatment of Parkinson's disease.

In conclusion, ZNF627 is a gene that has the potential to be a drug target for parkinson's disease. Its involvement in the regulation of Tau and other proteins that are important for the survival and growth of neurons makes it an attractive target for the development of new treatments for this neurodegenerative disorder. Further research is needed to determine the exact mechanisms by which ZNF627 contributes to the development and progression of parkinson's disease and to identify safe and effective ways to target it.

Protein Name: Zinc Finger Protein 627

Functions: May be involved in transcriptional regulation

The "ZNF627 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF627 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ZNF628 | ZNF629 | ZNF630 | ZNF638 | ZNF639 | ZNF641 | ZNF644 | ZNF646 | ZNF648 | ZNF649 | ZNF652 | ZNF652-AS1 | ZNF653 | ZNF654 | ZNF655 | ZNF658 | ZNF658B | ZNF66 | ZNF660 | ZNF662 | ZNF663P | ZNF664 | ZNF664-RFLNA | ZNF665 | ZNF667 | ZNF667-AS1 | ZNF668 | ZNF669 | ZNF670 | ZNF670-ZNF695 | ZNF671 | ZNF672 | ZNF674 | ZNF674-AS1 | ZNF675 | ZNF676 | ZNF677 | ZNF678 | ZNF679 | ZNF680 | ZNF681 | ZNF682 | ZNF683 | ZNF684 | ZNF687 | ZNF688 | ZNF689 | ZNF69 | ZNF691 | ZNF692 | ZNF695 | ZNF696 | ZNF697 | ZNF699 | ZNF7 | ZNF70 | ZNF700 | ZNF701 | ZNF702P | ZNF703 | ZNF704 | ZNF705A | ZNF705B | ZNF705CP | ZNF705EP | ZNF705G | ZNF706 | ZNF707 | ZNF708 | ZNF709 | ZNF71 | ZNF710 | ZNF711 | ZNF713 | ZNF714 | ZNF716 | ZNF717 | ZNF718 | ZNF721 | ZNF723 | ZNF724 | ZNF726 | ZNF727 | ZNF728 | ZNF729 | ZNF730 | ZNF732 | ZNF734P | ZNF735 | ZNF736 | ZNF737 | ZNF738 | ZNF74 | ZNF740 | ZNF746 | ZNF747 | ZNF749 | ZNF750 | ZNF75A | ZNF75CP